The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system

British Journal of Cancer

Volumn 86, Issue 7, 2002, Pages 1117-1123

  Burns, Alice S Y W ^a   Jaros, E ^b   Cole, M ^c   Perry, R ^b   Pearson, A J ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Bax; Bcl 2; Central primitive neuroectodermal tumours; DNA sequencing; p53 protein; Waf 1

Indexed keywords

CELL DNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DO 7; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CANCER; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEUROECTODERM TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; ANTIBODIES, MONOCLONAL; BCL-2-ASSOCIATED X PROTEIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBELLUM; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SEQUENCE ANALYSIS, DNA; SEX FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85047698914     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600151     Document Type: Article

References (33)

1. p53 gene mutation and Mdm2 gene amplification are uncommon in medulloblastoma
2. Microsatellite analysis of loss of heterozygosity on chromosomes 9q 11p and 17p in medulloblastomas
3. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha
4. p53 gene mutations in medulloblastoma. Immunohistochemistry gel shift analysis and sequencing
5. p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data oestrogen receptor status MIB1 expression p53 gene and protein alterations and relapse-free survival
6. Medulloblastoma in pediatric age: A single institution review of prognostic factors
7. Analysis of TP53 tumour suppressor gene in hepatocellular carcinomas from Britain
8. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas
9. WAF1 a potential mediator of p53 tumor suppression
10. Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implication for the biology for the biology of medulloblastoma
11. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
12. Hypoxia induces accumulation of p53 protein but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status
13. The tumor suppressor protein p53: A receptor to genotoxic stress that controls cell growth and survival
14. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD
15. p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis
16. p53 the cellular gatekeeper for growth and division
17. WAF1/CIP1 expression through mitogen-activated protein kinase
18. Identification of a p53-dependent negative response element in the bcl-2 gene
19. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
20. Tumor suppressor p53 is a direct transcriptional activator of the human bax Gene
21. Differential p53 p21 mdm2 and Rb regulation in glioma cell lines that overexpress wild-type p53
22. Medulloblastoma: A population-based study of 532 cases
23. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress
24. Infrequent p53 gene mutations in medulloblastomas
25. Wild-type p53 binds to the TATA-binding protein and represses transcription
26. Clinical and pathological association with p53 tumour suppressor gene mutations and expression of p21 WAF/CIP1 in colorectal carcinoma
27. Staging scoring and grading of medulloblastoma
28. Loss of Heterozygosity on 6q 16q and 17p in human central nervous system primitive neuroectodermal tumors
29. Medulloblastoma in childhood: Results of radical resection and low-dose neuraxis radiation therapy
30. The mutation status of PAX3 and p53 genes in medulloblastoma
31. Influence of a child's sex on medulloblastoma outcome
32. Prognostic importance of DNA ploidy in medulloblastoma of childhood